OS Therapies Inc — financial figures as filed
CIK 1795091 · 4 fiscal years on record
Aggregates
computed from the figures belowExplainable annual analytics
latest annual period where both published inputs exist| Metric | Value | Fiscal year | Inputs | Source tags |
|---|---|---|---|---|
| Return on assets | -420.4% | FY2025 | Net income: -$28.8MTotal assets: $6.8M | NetIncomeLoss / Assets |
| Return on equity | 471.7% | FY2025 | Net income: -$28.8MShareholders equity: -$6.1M | NetIncomeLoss / StockholdersEquity |
| Liabilities / assets | 173.5% | FY2025 | Total liabilities: $11.9MTotal assets: $6.8M | Liabilities / Assets |
Not computed: Gross margin — both metrics are not available for a common annual period; Operating margin — both metrics are not available for a common annual period; Net margin — both metrics are not available for a common annual period; Operating cash-flow margin — both metrics are not available for a common annual period; Cash / assets — both metrics are not available for a common annual period.
Mapping completeness
9 of 129 of 12 canonical metrics were filled from this company's filings through the explicit tag map. Tags outside that map are recorded and counted, and are never used as a value.
Not on record for this company: Revenue, Gross profit, Cash and equivalents. This means the figure was not disclosed in a form we accept, not that it is zero.
Annual figures
4 fiscal years shown| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating income | -$28.7M | -$6.8M | -$4.3M | — |
| Net income | -$28.8M | -$8.9M | -$7.8M | — |
| Operating cash flow | -$14.2M | -$7.3M | -$3M | — |
| Total assets | $6.8M | $5.5M | $798.1K | — |
| Total liabilities | $11.9M | $4.7M | $24.8M | — |
| Shareholders equity | -$6.1M | -$5.2M | -$24M | -$17.6M |
| Shares outstanding | 37,113,082 | 20,869,908 | 5,340,000 | — |
| EPS, basic | -$0.98 | -$0.88 | -$1.46 | — |
| EPS, diluted | -$0.98 | -$0.88 | -$1.46 | — |
Quarterly figures
10 fiscal quarters shown| Metric | 2026 Q1 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$10.2M | -$6.9M | -$4.8M | -$5M | -$2.4M | -$779.8K | -$630.2K | -$622.2K | -$1.5M | -$1M |
| Net income | -$10.4M | -$6.9M | -$4.5M | -$3.9M | -$2.9M | -$1.6M | -$1.5M | -$2M | -$2.5M | -$1.8M |
| Operating cash flow | -$4.6M | — | — | -$3.4M | — | — | -$641.7K | — | — | -$428.2K |
| Total assets | $7.3M | $9M | $10.3M | $4.2M | $2M | $1.3M | $1M | — | — | — |
| Total liabilities | $17.1M | $4.2M | $3.6M | $3.6M | $2.7M | $28.4M | $26.6M | — | — | — |
| Shareholders equity | -$10.8M | $3.6M | $4.9M | -$4.2M | -$707.1K | -$27.1M | -$25.5M | -$22.5M | -$21.3M | -$18.7M |
| Shares outstanding | 39,278,192 | 33,269,981 | 29,664,916 | 21,347,315 | 21,180,883 | 5,991,041 | 11,982,082 | — | — | — |
| EPS, basic | -$0.27 | -$0.21 | -$0.19 | -$0.18 | -$0.18 | -$0.26 | -$0.25 | -$0.38 | -$0.47 | — |
| EPS, diluted | -$0.27 | -$0.21 | -$0.19 | -$0.18 | -$0.18 | -$0.26 | -$0.25 | -$0.38 | -$0.47 | — |
Latest figure against the peer median
all 722 companies with figures on record| Metric | Latest annual figure | Peer median | Difference | Companies in group | Source tag |
|---|---|---|---|---|---|
| Operating income · FY2025 | -$28.7M | -$3.8M | −656.4% | 591 | OperatingIncomeLoss |
| Net income · FY2025 | -$28.8M | $2.4M | −1,275.1% | 716 | NetIncomeLoss |
| Operating cash flow · FY2025 | -$14.2M | $20.1M | −170.8% | 715 | NetCashProvidedByUsedInOperatingActivities |
| Total assets · FY2025 | $6.8M | $1.1B | −99.4% | 720 | Assets |
| Total liabilities · FY2025 | $11.9M | $458.2M | −97.4% | 664 | Liabilities |
| Shareholders equity · FY2025 | -$6.1M | $301M | −102.0% | 716 | StockholdersEquity |
| Shares outstanding · FY2025 | 37,113,082 | 49,628,137 | −25.2% | 606 | CommonStockSharesOutstanding |
| EPS, basic · FY2025 | -$0.98 | $0.05 | −2,060.0% | 678 | EarningsPerShareBasic |
| EPS, diluted · FY2025 | -$0.98 | $0.03 | −4,020.0% | 678 | EarningsPerShareDiluted |
Where the numbers come from
every figure traces to a filing| Metric | Fiscal period | Period end | Filed | Form | Accession | XBRL tag |
|---|---|---|---|---|---|---|
| Operating income | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | OperatingIncomeLoss |
| Net income | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | NetIncomeLoss |
| Operating cash flow | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | NetCashProvidedByUsedInOperatingActivities |
| Total assets | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | Assets |
| Total liabilities | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | Liabilities |
| Shareholders equity | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | StockholdersEquity |
| Shares outstanding | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | CommonStockSharesOutstanding |
| EPS, basic | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | EarningsPerShareBasic |
| EPS, diluted | FY2025 | 2025-12-31 | 2026-03-31 | 10-K | 0001213900-26-036629 | EarningsPerShareDiluted |
Source: U.S. Securities and Exchange Commission, EDGAR company facts · as of 2026-03-31